Altium Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Altium Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400,000	Closed	-$4.01M	–	144
2022 Q3	$4.01M	Hold	400,000	–	–	1.47%	22
2022 Q2	$3.96M	Hold	400,000	–	–	1.58%	19
2022 Q1	$3.94M	Hold	400,000	–	–	1.32%	32
2021 Q4	$3.9M	Hold	400,000	–	–	1.08%	36
2021 Q3	$3.91M	Hold	400,000	–	–	1.03%	40
2021 Q2	$3.94M	Buy	+400,000	New	+$3.94M	0.91%	40

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Altium Capital Management's EUCR Position: Q4 2022 in Review

Altium Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 400,000 shares — an estimated $4.01M sold.

Altium Capital Management first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $4.01M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Altium Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Altium Capital Management sold 400,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $4.01M.
Altium Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
Altium Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $4.01M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.